Product Description
Lpathomab is a first-in-class, humanized monoclonal antibody targeting lysophosphatidic acid (LPA), and has shown positive activity in animal models of neuropathic pain induced by a variety of conditions, including nerve injury, type 1 and 2 diabetes, inflammation, and chemotherapeutic administration. Lpathomab was discovered using Lpath's internal drug-discovery engine and antibodies developed via this discovery engine are designed to target bioactive signaling lipids that are involved in neuropathic pain, neurotrauma, cancer, inflammatory disorders and many other diseases. (Sourced from: https://www.prnewswire.com/news-releases/lpath-reports-favorable-results-from-phase-1-study-of-lpathomab-300253102.html; http://www.lpath.com)
Mechanisms of Action: LPAR1 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lpath
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02341508 |
LT3114-NPP-001 | P1 |
Completed |
Healthy Volunteers |
2016-03-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|